First- and second-line treatment strategies for chronic phase CML using tyrosine kinase inhibitors – present status discussed at ASH 2009 | springermedizin.at

Springer Medizin Österreich

nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.10.2010 | ASH report

First- and second-line treatment strategies for chronic phase CML using tyrosine kinase inhibitors – present status discussed at ASH 2009

verfasst von: T. Kühr

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Anzeige

Vorheriger Artikel Very low rates of neutropenic complications and chemotherapy dose modifications in early breast cancer patients receiving adjuvant FEC-100 or TAC and an individualised G-CSF and anti-infective support: results of a retrospective chart review

Nächster Artikel Consideration of exposure to pharmacological agents helps to avoid diagnostic pitfalls in bone marrow histopathology

Titel: First- and second-line treatment strategies for chronic phase CML using tyrosine kinase inhibitors – present status discussed at ASH 2009
verfasst von: T. Kühr
Publikationsdatum: 01.10.2010
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2010
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-010-0211-x

Weitere Artikel der Ausgabe 3/2010

Hepatocellular carcinoma – a challenge for oncologists

Editorial

Robotic surgery in thoracic cancer

Short review

Pharmacoeconomy in cancer therapy

Leading article

Very low rates of neutropenic complications and chemotherapy dose modifications in early breast cancer patients receiving adjuvant FEC-100 or TAC and an individualised G-CSF and anti-infective support: results of a retrospective chart review

Original report

Robotic surgery, a variant of minimally invasive surgery for gynaecological malignancies

Editorial

Hepatocellular carcinoma – new trends

Short review